



Alaska Medical Assistance DUR Committee Meeting
Friday, April 29, 2016
Frontier Building, 3601 C Street; Room 890/896
1:00pm
1.800.315.6338, access code 24251#

Agenda

- (1) Review of minutes from the last meeting
- (2) Review of agenda
- (3) Comments/Suggestions from Committee members
 - a. Lyrica
- (4) Prospective Drug Utilization Review / Clinical Topic Areas:
 - a. New Prescription Medications (Interim PA List – 6 month review)
 - b. Review of existing Prior Authorizations, Quantity Limits, Edits
 - i. Periodic Review
 1. H.P. Acthar Gel
 2. Human Growth Hormone / Serostim
 3. Lidoderm Patch
 - c. Proposed New Prior Authorization, Quantity Limits, Edits
 1. Belsomra
 2. PCSK9 Inhibitors
 3. Tecfidera
 4. Metformin ER Step Therapy

<<Break>>

- (5) Past Intervention Informational Updates
- (6) FDA/DEA Updates
 - a. FDA Drug Safety Communications
 - i. Heart failure risk with saxagliptin and alogliptin [4/5/2016]
 - ii. Metformin labeling changes [4/8/2016]
 - iii. TBD
- (7) FAERS Report
- (8) Quality Measures
- (9) Standing Reviews
- (10) End of Public Meeting